FDA Grants Accelerated Approval to Sonrotoclax for Relapsed or Refractory Mantle Cell Lymphoma By Ogkologos - May 27, 2026 238 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BGB-11417-201 study Source RELATED ARTICLESMORE FROM AUTHOR Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant MOST POPULAR ESMO Welcomes European Parliament (EP) Draft Report on Psychosocial Risks at... April 2, 2026 Program Helps Medically Underserved, Minority Cancer Survivors Be More Active July 3, 2024 Are New Immune-Based Treatments for Kidney and Pancreatic Cancer on the... April 23, 2025 Reunión anual de la American Society of Clinical Oncology de 2022:... June 5, 2022 Load more HOT NEWS Cancer Research UK’s Race for Life celebrates its 30th year by... Activity and Safety of Regorafenib Plus Nivolumab in First-Line Treatment for... EMA Recommends Extension of Therapeutic Indications for Cabozantinib Diagnosed With Breast Cancer At 24, Her Biggest Fear Wasn’t Death...
